natgillin/translations-raw huggingface dataset:
Samtidig administration af Possia og heparin, enoxaparin eller desmopressin påvirkede ikke P- aktiveret partiel tromboplastintid (aPTT), aktiveret koagulationstid eller faktor Xa-analyser.
Co-administration of Possia with heparin, enoxaparin or desmopressin had no effect on activated partial thromboplastin time (aPTT), activated coagulation time (ACT) or factor Xa assays.
Samtidig administration af Possia øgede digoxins Cmax med 75 % og AUC med 28 %.
Concomitant administration of Possia increased the digoxin Cmax by 75% and AUC by 28%.
Samtidig administration af potent CYP3A4-hæmmer og dasatinib anbefales derfor ikke (se pkt.
Therefore, in patients receiving dasatinib, coadministration of a potent CYP3A4 inhibitor is not recommended (see section 4.5).
Samtidig administration af potente CYP3A4- hæmmere (f.eks. ketoconazol, clarithromycin, itraconazol, ritonavir, telithromycin) kan hæmme metabolisering af vilanterol, og øge den systemiske eksponering.
Concomitant administration of strong CYP3A4 inhibitors (e.g. ketoconazole, clarithromycin, itraconazole, ritonavir, telithromycin) may inhibit the metabolism of, and increase the systemic exposure to, vilanterol.
Samtidig administration af potente CYP3A4- induktorer kan nedsætte Ketoconazole HRAs biotilgængelighed.
Coadministration of potent enzyme inducers of CYP3A4 may decrease the bioavailibity of Ketoconazole HRA.
Samtidig administration af potente CYP3A4-induktorer som f.eks. carbamazepin, phenobarbital, phenytoin, rifabutin, rifampicin og perikon med ponatinib bør undgås, og alternativer til CYP3A4- induktorer bør søges, medmindre fordelen opvejer den mulige risiko for undereksponering af ponatinib.
Co-administration of strong CYP3A4 inducers such as carbamazepine, phenobarbital, phenytoin, rifabutin, rifampicin, and St. John’s Wort with ponatinib should be avoided, and alternatives to the CYP3A4 inducer should be sought, unless the benefit outweighs the possible risk of ponatinib underexposure.
Samtidig administration af potente induktorer af P-gp, glukuronidering og/eller CYP3A4 (f.eks. rifampicin, rifabutin, carbamazepin, phenytoin eller perikon [Hypericum perforatum]) kan medføre en suboptimal eksponering af vemurafenib og bør undgås.
Concomitant administration of potent inducers of P-gp, glucuronidation, and/or CYP3A4 (e.g. rifampicin, rifabutin, carbamazepine, phenytoin or St John’s Wort [Hypericum perforatum]) may lead to suboptimal exposure to vemurafenib and should be avoided.
Samtidig administration af potentielle nephrotoxiske præparater skal undgås.
Concurrent administration of potential nephrotoxic drugs should be avoided.
Samtidig administration af potentielle P-glycoprotein-hæmmere så som ciclosporin, ketoconazol, erythromycin, clarithromycin, verapamil, dronedaron og amiodaron anbefales ikke (se pkt.
Co-administration of potent P-glycoprotein inhibitors such as cyclosporine, ketoconazole, erythromycin, clarithromycin, verapamil, dronedarone and amiodarone is not recommended (see sections 4.5 and 5.2).
Samtidig administration af potentielt nyretoksiske stoffer bør undgås, da der kan være en forøget risiko for renal toksisitet.
Concurrent administration of potentially nephrotoxic medicines should be avoided as there might be an increased risk of renal toxicity.
Samtidig administration af PREZISTA administreret sammen med lavdosis ritonavir og disse glukokortikoider anbefales ikke, medmindre den mulige fordel ved behandlingen opvejer risikoen ved systemiske kortikosteroideffekter.
Concomitant administration of PREZISTA co-administered with low dose ritonavir and these glucocorticoids is not recommended unless the potential benefit of treatment outweighs the risk of systemic corticosteroid effects.
Samtidig administration af PREZISTA med lavdosis ritonavir og ticagrelor er kontraindiceret.
Concomitant administration of PREZISTA with low dose ritonavir with ticagrelor is contraindicated.
Samtidig administration af PREZISTA/ritonavir og ticagrelor er kontraindiceret.
Concomitant administration of PREZISTA with low dose ritonavir with ticagrelor is contraindicated.
Samtidig administration af prikbladet perikum, en P-gp-inducer, kan reducere plasmakoncentrationerne af tenofoviralafenamid, hvilket kan forårsage svigtende terapeutisk virkning og udvikling af resistens.
Co-administration of St. John’s wort, a P-gp inducer, may decrease tenofovir alafenamide plasma concentrations, which may result in loss of therapeutic effect and development of resistance.
Samtidig administration af probenecid og mycophenolatmofetil forhøjer MPAG's plasma-AUC 3 gange hos aber.
Co-administration of probenecid with mycophenolate mofetil in monkeys raises plasma AUC of MPAG by 3-fold.
Samtidig administration af propranolol kan medføre ændret automatik (overdreven bradykardi, sinus stop) sino-atrial og atrioventrikulære ledningsforstyrrelser og øget risiko for ventrikulære arytmier (torsades de pointes) samt hjertesvigt.
Co-administration with propranolol can cause altered automaticity (excessive bradycardia, sinus arrest), sino-atrial and atrio-ventricular conduction disorders, and increased risk of ventricular arrhythmias (torsades de pointes) along with heart failure.
Samtidig administration af protonpumpehæmmere gav ingen relevant påvirkning af eksponeringen for edoxaban.
Co-administration of proton- pump inhibitors had no relevant impact on edoxaban exposure.
Samtidig administration af Rasilez havde ingen signifikant indvirkning på atorvastatins, metformins eller amlodipins farmakokinetik.
Co- administration of Rasilez had no significant impact on atorvastatin, metformin or amlodipine pharmacokinetics.
Samtidig administration af REYATAZ kan medføre højere salmeterol-koncentration og øget risiko for salmeterol-relaterede bivirkninger.
Co-administration with REYATAZ may result in increased concentrations of salmeterol and an increase in salmeterol-associated adverse events.
Samtidig administration af REYATAZ kan medføre øget koncentration af PDE5- hæmmeren og øget risiko for PDE5- relaterede bivirkninger, inklusive hypotension, synsforstyrrelser og priapisme.
Co- administration with REYATAZ may result in increased concentrations of the PDE5 inhibitor and an increase in PDE5-associated adverse events, including hypotension, visual changes, and priapism.
Samtidig administration af REYATAZ med ritonavir kræver overvågning for sedation og kognitiv påvirkning.
Co-administration warrants clinical monitoring for sedation and cognitive effects.
Samtidig administration af REYATAZ/ritonavir kan medføre højere salmeterol-koncentration og øget risiko for salmeterol-relaterede bivirkninger.
Co-administration with REYATAZ/ritonavir may result in increased concentrations of salmeterol and an increase in salmeterol- associated adverse events.
Samtidig administration af REYATAZ/ritonavir og quetiapin er kontraindiceret, da REYATAZ kan øge quetiapin-relateret toksicitet.
Co-administration of REYATAZ/ritonavir with quetiapine is contraindicated as may increase quetiapine-related toxicity.
Samtidig administration af rifabutin, en kraftig CYP3A- inducer, kan reducere plasmakoncentrationerne af cobicistat og elvitegravir signifikant, hvilket kan forårsage svigtende terapeutisk virkning og udvikling af resistens.
Co-administration of rifabutin, a potent CYP3A inducer, may significantly decrease cobicistat and elvitegravir plasma concentrations, which may result in loss of therapeutic effect and development of resistance.
Samtidig administration af rifabutin, en kraftig CYP3A- inducer, kan reducere plasmakoncentrationerne af cobicistat og elvitegravir signifikant, hvilket kan forårsage svigtende terapeutisk virkning og udvikling af resistens.
Co-administration of rifabutin, potent CYP3A inducer, may significantly decrease cobicistat and elvitegravir plasma concentrations, which may result in loss of therapeutic effect and development of resistance.
Samtidig administration af rifabutin, en potent CYP3A- induktor, kan reducere plasmakoncentrationerne af cobicistat signifikant.
Co-administration of rifabutin, a potent CYP3A inducer, may significantly decrease cobicistat plasma concentrations.
Samtidig administration af rifampicin (en hæmmer af organisk anion-transport-polypeptid [OATP], en stærk CYP3A- og 2C19-inducer samt inducer af P-glykoprotein (P-gp) og uridindifosfatglukuronosyl- transferaser [UGTs]) er blevet kædet sammen med en forbigående stigning (omtrent en fordobling) i eksponeringen af ambrisentan efter første dosis hos raske frivillige personer.
Co-administration of rifampicin (an inhibitor of Organic Anion Transporting Polypeptide [OATP], a strong inducer of CYP3A and 2C19, and inducer of P-gp and uridine-diphospho- glucuronosyltransferases [UGTs]) was associated with a transient (approximately 2-fold) increase in ambrisentan exposure following initial doses in healthy volunteers.
Samtidig administration af rilpivirin og nogle ritonavirforstærkede proteasehæmmere har medført en stigning i rilpivirin- plasmakoncentrationen.
Concomitant use of rilpivirine with some ritonavir-boosted protease inhibitors has demonstrated an
Samtidig administration af rilpivirin og nogle ritonavirforstærkede proteasehæmmere har medført en stigning i rilpivirin- plasmakoncentrationen.
Concomitant use of rilpivirine with some ritonavir-boosted protease inhibitors has demonstrated an increase in the plasma concentrations of rilpivirine.
Samtidig administration af riociguat og Norvir anbefales ikke (se pkt.4.4 og produktresuméet for riociguat).
The coadministration of riociguat with Norvir is not recommended (see section 4.4 and refer to riociguat SmPC).
Samtidig administration af Riprazo havde ingen signifikant indvirkning på atorvastatins, metformins eller amlodipins farmakokinetik.
Co- administration of Riprazo had no significant impact on atorvastatin, metformin or amlodipine pharmacokinetics.
Samtidig administration af ritonavir og ketoconazol medførte øget incidens af gastrointestinale og hepatiske bivirkninger.
Co- administration of ritonavir and ketoconazole caused an increased incidence of gastrointestinal and hepatic adverse events.
Samtidig administration af Ritonavir vil sandsynligvis resultere i forhøjede plasmakoncentrationer af amiodaron, bepridil, dronedaron, encainid, flecainide, propafenon og kinidin og er derfor kontraindiceret (se sektion 4.3).
Ritonavir co-administration is likely to result in increased plasma concentrations of amiodarone, bepridil, dronedarone, encainide, flecainide, propafenone, and quinidine and is therefore contraindicated (see section 4.3).
Samtidig administration af Ritonavir vil sandsynligvis resulterer i forhøjet plasmakoncentration af cisaprid og er derfor kontraindiceret (se pkt 4.3).
Cisapride Ritonavir co-administration is likely to result in increased plasma concentrations of cisapride and is therefore contraindicated (see section 4.3).
Samtidig administration af rivaroxaban og lopinavir/ritonavir kan øge rivaroxaban- eksponeringen, hvilket kan øge risikoen for blødning (se pkt.
Co-administration of rivaroxaban and lopinavir/ritonavir may increase rivaroxaban exposure which may increase the risk of bleeding.
Samtidig administration af rivaroxaban og Tybost anbefales ikke.
Co-administration of rivaroxaban and Tybost is not recommended.
Samtidig administration af salicylater og valproinsyre kan medføre nedsat proteinbinding af valproinsyre og hæmme metaboliseringen af valproinsyre, hvilket medfører øget serum koncentration af total og frit valproinsyre.
The concomitant administration of salicylates and valproic acid may result in decreased valproic acid protein binding and inhibition of valproic acid metabolism resulting in increased serum levels of total and free valproic acid.
Samtidig administration af salmeterol og Aptivus plus lavdosis ritonavir anbefales ikke.
Concurrent administration of Aptivus, co-administered with low dose ritonavir, is not recommended.
Samtidig administration af Samsca og anden behandling for hyponatriæmi eller medicin, der øger serum-natrium, frarådes under den indledende behandling eller for andre patienter med meget lave baselinekoncentrationer af serum-natrium (se pkt.
Co-administration of Samsca with other treatments for hyponatraemia, and medications that increase serum sodium concentration, is not recommended during initial treatment or for other patients with very low baseline serum sodium concentrations (see section 4.5).
Samtidig administration af saquinavir og ritonavir har medført svære bivirkninger, hovedsagelig diabetisk ketoacidose og leverpåvirkninger, især hos patienter med præeksisterende leverlidelse.
Co-administration of saquinavir and ritonavir has led to severe adverse events, mainly diabetic ketoacidosis and liver disorders, especially in patients with pre- existing liver disease.
Samtidig administration af saxagliptin og andre CYP3A4/5-induktorer end rifampicin (såsom carbamazepin, dexamethason, phenobarbital og phenytoin) er ikke undersøgt og kan resultere i nedsat plasmakoncentration af saxagliptin og øget koncentration af hovedmetabolitten.
The co-administration of saxagliptin and CYP3A4/5 inducers, other than rifampicin (such as carbamazepine, dexamethasone, phenobarbital and phenytoin) has not been studied and may result in decreased plasma concentration of saxagliptin and increased concentration of its major metabolite.
Samtidig administration af Seebri Breezhaler og oralt inhaleret indacaterol, som er en adrenerg beta2- agonist, havde ingen indvirkning på farmakokinetikken for de to lægemidler under steady state- forhold for begge aktive stoffer.
Concomitant administration of Seebri Breezhaler and orally inhaled indacaterol, a beta2-adrenergic agonist, under steady-state conditions of both active substances did not affect the pharmacokinetics of either medicinal product.
Samtidig administration af selektive serotonin-genoptagelseshæmmere (SSRIer) eller selektive serotonin-noradrenalin-genoptagelseshæmmere (SNRIer)
Co-medication with selective serotonin re-uptake inhibitors (SSRIs) or selective serotonin norepinephrine re-uptake inhibitors (SNRIs)
Samtidig administration af Senshio og fluconazol
Co-administration of Senshio with fluconazole
Samtidig administration af simeprevir og efavirenz, et aktivt stof i Atripla, resulterede i signifikant nedsat simeprevir- plasmakoncentration på grund af efavirenzforårsaget CYP3A-induktion, som kan resultere i manglende terapeutisk virkning af simeprevir.
Concomitant administration of simeprevir with efavirenz, a component of Atripla, resulted in significantly decreased plasma concentrations of simeprevir due to CYP3A induction by efavirenz, which may result in loss of therapeutic effect of simeprevir.
Samtidig administration af simvastatin eller lovastatin og REYATAZ er kontraindiceret på grund af øget risiko for myopati, inklusive rabdomyolyse (se pkt.
Co-administration of simvastatin or lovastatin with REYATAZ is contraindicated due to an increased risk of myopathy including rhabdomyolysis.
Samtidig administration af sirolimus (2 mg enkeltdosis) og flerdosisadministration af oral voriconazol (400 mg hver 12. time i 1 dag, og derefter 100 mg hver 12. time i 8 dage) til raske personer er rappor- teret at øge sirolimus Cmax med gennemsnitligt 7 gange og AUC med gennemsnitligt 11 gange.
Co-administration of sirolimus (2 mg single dose) with multiple-dose administration of oral voriconazole (400 mg every 12 hours for 1 day, then 100 mg every 12 hours for 8 days) in healthy subjects has been reported to increase sirolimus Cmax and AUC by an average of 7-fold and 11-fold respectively.
Samtidig administration af sirolimus (2 mg enkeltdosis) og flerdosisadministration af oral voriconazol (400 mg hver 12. time i 1 dag, og derefter 100 mg hver 12. time i 8 dage) til raske personer er rappor- teret at øge sirolimus Cmax med gennemsnitligt 7 gange og AUC med gennemsnitligt 11 gange.
Co-administration of sirolimus (2 mg single dose) with multiple-dose administration of oral voriconazole (400 mg every 12 hours for 1 day, then 100 mg every 12 hours for 8 days) in healthy subjects has been reported to increase sirolimus Cmax and AUC by an average of 7-fold and 11-fold, respectively.
Samtidig administration af sirolimus og ACE-hæmmere har ført til angioødemlignende reaktioner.
The concomitant administration of sirolimus and angiotensin-converting enzyme inhibitors has resulted in angioneurotic oedema-type reactions.
Samtidig administration af spironolakton og ACE-hæmmere eller andre kaliumbesparende lægemidler (som angiotensionreceptorblokkere, ß-blokkere, calciumkanalblokkere, etc.) kan potentielt føre til hyperkaliæmi. (se afsnit 4.5).
Concomitant administration of spironolactone with ACE-inhibitors and other potassium-sparing drugs (as angiotensin receptor blockers, ß-blockers, calcium channels blockers, etc) may potentially lead to hyperkalaemia (see section "Special precautions for use in animals").
Samtidig administration af spironolakton og ACE-hæmmere eller andre kaliumbesparende lægemidler (som angiotensionreceptorblokkere, ß-blokkere, calciumkanalblokkere, etc.) kan potentielt føre til hyperkaliæmi. (se afsnit 4.5).
Concomitant administration of spironolactone with ACE-inhibitors and other potassium-sparing drugs (as angiotensin receptor blockers, ß-blockers, calcium channels blockers…etc) may potentially lead to hyperkalaemia (see section 4.5).
Samtidig administration af Stalevo og non-selektive monoaminooxidase (MAO-A og MAO-B)- hæmmere (f.eks. phenelzin, tranylcypromin).
Coadministration of Stalevo with non-selective monoamine oxidase (MAO-A and MAO-B) inhibitors (e.g. phenelzine, tranylcypromine).
Samtidig administration af stoffer, som påvirker CYP2D6- eller CYP3A4-aktivitet, kan ændre eliglustat- plasmakoncentrationerne.
Concomitant administration of substances affecting CYP2D6 or CYP3A4 activity may alter eliglustat plasma concentrations.
Samtidig administration af stoffer, som ændrer immunfunktionen (f.eks. kortikosteroider eller non- steroide anti-inflammatoriske lægemidler) kan nedsætte veterinærlægemidlets virkning.
Concurrent administration of substances which alter immune function (e.g. corticosteroids or non steroidal anti-inflammatory drugs) may reduce the efficacy of the product.
Samtidig administration af stoffer, som ændrer immunfunktionen (f.eks. kortikosteroider eller non- steroide anti-inflammatoriske lægemidler) kan reducere veterinærlægemidlets virkning.
Concurrent administration of substances which alter immune function (e.g. corticosteroids or non steroidal anti-inflammatory drugs) may reduce the efficacy of the product.
Samtidig administration af Stribild kan føre til øgede plasmakoncentrationer af disse lægemidler, hvilket er forbundet med risikoen for alvorlige og/eller livstruende reaktioner.
Co-administration with Stribild may result in increased plasma concentrations of these drugs, which is associated with the potential for serious and/or life- threatening reactions.
Samtidig administration af Stribild kan medføre øget tenofovir- eksponering.
Co-administration with Stribild may lead to increased tenofovir exposure.
Samtidig administration af Stribild og andre lægemidler metaboliseres primært af CYP3A, såsom amiodaron, quinidin, cisaprid, pimozid, alfuzosin og sildenafil mod pulmonal arteriel hypertension er kontraindiceret (se pkt.
Co-administration of Stribild and other medicinal products primarily metabolised by CYP3A such as amiodarone, quinidine, cisapride, pimozide, alfuzosin and sildenafil for pulmonary arterial hypertension is contraindicated (see section 4.3).
Samtidig administration af Stribild og nogle lægemidler, som inducerer CYP3A såsom prikbladet perikum (Hypericum perforatum), rifampicin, carbamazepin, phenobarbital og phenytoin kan føre til signifikant reducerede plasmakoncentrationer af cobicistat og elvitegravir, hvilket kan forårsage svigtende terapeutisk virkning og udvikling af resistens (se pkt.
Co-administration of Stribild and some medicinal products that induce CYP3A such as St. John’s wort (Hypericum perforatum), rifampicin, carbamazepine, phenobarbital and phenytoin may result in significantly decreased cobicistat and elvitegravir plasma concentrations, which may result in loss of therapeutic effect and development of resistance (see section 4.3).
Samtidig administration af Stribild og orale antikonceptiva, der indeholder andre progestagener end norgestimat er ikke undersøgt og bør derfor undgås.
Co-administration of Stribild with oral contraceptives containing progestagens other than norgestimate has not been studied and therefore should be avoided.
Samtidig administration af Stribild og orale antikonceptiva, der indeholder andre progestagener end norgestimat er ikke undersøgt og bør derfor undgås.
Co-administration of Stribild with oral contraceptives containing progestagens other than norgestimate has not been studied and, therefore, should be avoided.
Samtidig administration af svage CYP3A4-hæmmere forventes at øge eksponeringen for lopitamid.
Weak CYP3A4 inhibitors are expected to increase the exposure of lomitapide when taken simultaneously.
Samtidig administration af Sycrest og lægemidler, der både er substrater og inhibitorer af CYP2D6, bør derfor håndteres med forsigtighed.
Therefore, Sycrest should be co-administered cautiously with medicinal products that are both substrates and inhibitors for CYP2D6.
Samtidig administration af tacrolimus anbefales ikke.
Concomitant treatment with tacrolimus is not recommended.
Samtidig administration af Tekturna havde ingen signifikant indvirkning på atorvastatins, valsartans, metformins eller amlodipins farmakokinetik.
Co- administration of Tekturna had no significant impact on atorvastatin, valsartan, metformin or amlodipine pharmacokinetics.
Samtidig administration af telaprevir og CYP3A- og/eller P-gp-inducere kan nedsætte telaprevir plasmakoncentrationen.
Co- administration of telaprevir and medicinal products that induce CYP3A and/or P-gp may decrease telaprevir plasma concentrations.
Samtidig administration af telaprevir og CYP3A- og/eller P-gp-inducere kan nedsætte telaprevir- plasmakoncentrationen.
Co- administration of telaprevir and medicinal products that induce CYP3A and/or P-gp may decrease telaprevir plasma concentrations.
Samtidig administration af telaprevir og CYP3A- og/eller P-gp-inducere kan nedsætte telaprevir-plasmakoncentrationen.
Co- administration of telaprevir and medicinal products that induce CYP3A and/or P-gp may decrease telaprevir plasma concentrations.
Samtidig administration af tenofovirdisoproxil og didanosin
Co-administration of tenofovir disoproxil and didanosine:
Samtidig administration af tenofovirdisoproxilfumarat og cobicistat forventes at øge tenofovirplasmakoncentrationen.
Co-administration of tenofovir disoproxil fumarate with cobicistat is expected to increase tenofovir plasma concentration.
Samtidig administration af tenofovirdisoproxilfumarat og didanosin i en dosis på 400 mg dagligt er blevet forbundet med en signifikant reduktion i antallet af CD4-celler, muligvis på grund af en intracellulær interaktion, der forhøjer fosforyleret (dvs. aktivt) didanosin.
Co-administration of tenofovir disoproxil fumarate and didanosine at a dose of 400 mg daily has been associated with a significant decrease in CD4 cell count, possibly due to an intracellular interaction increasing phosphorylated (i.e. active) didanosine.
Samtidig administration af tenofovirdisoproxilfumarat og didanosin medførte en stigning på 40-60% i systemisk eksponering for didanosin, som kan øge risikoen for didanosin-relaterede bivirkninger.
Co-administration of tenofovir disoproxil fumarate and didanosine results in a 40-60% increase in systemic exposure to didanosine that may increase the risk for didanosine-related adverse reactions.
Samtidig administration af tenofovirdisoproxilfumarat og didanosin resulterer i en 40-60% forhøjelse i systemisk eksponering for didanosin, hvilket kan forøge risikoen for didanosin-relaterede bivirkninger.
Co-administration of tenofovir disoproxil fumarate and didanosine results in a 40-60% increase in systemic exposure to didanosine that may increase the risk of didanosine-related adverse reactions.